Background
==========

The concept of the metabolic syndrome has developed in stages over the past 80 years; it is now recognized that the combination of abdominal obesity, glucose metabolism abnormalities, hypertension, and dyslipidemia, accompanied by prothrombotic and proinflammatory states, leads to type 2 diabetes and vascular diseases, including coronary heart disease and stroke \[[@B1],[@B2]\].

Metabolic syndrome predicts total, cardiovascular, and coronary heart disease mortality; in fact, the presence of even 1 or 2 components of the metabolic syndrome increases overall mortality compared with the absence of any component of the metabolic syndrome \[[@B3]-[@B6]\]. A 65% excess risk has been estimated for cardiovascular disease in individuals with the metabolic syndrome \[[@B7]\]. Metabolic syndrome even predicts the occurrence of sudden death, independent of the presence of other cardiovascular risk factors \[[@B8]\]. Metabolic syndrome also predicts the incidence and progression of carotid atherosclerosis \[[@B9]\].

As reviewed recently, worldwide prevalence of metabolic syndrome ranges from \<10% to as much as 84%, depending on age, region, urban or rural environment, ethnicity, and the definition of metabolic syndrome used \[[@B10]-[@B12]\]. In the United States, between 1994 and 2000, prevalence of metabolic syndrome in adults increased from 23% to 27% along with an increase in obesity and physical inactivity \[[@B13]\]. Developing regions like Latin America, undergoing sea change in the lifestyle factors contributing to the metabolic syndrome, may see even greater increases in prevalence over a relatively short span of time. Local public health and clinical efforts to stem morbidity and mortality from the metabolic syndrome must be based on the relevant local prevalence of its components. The Cardiovascular Risk Factor Multiple Evaluation in Latin America (CARMELA) study investigated risk factors for cardiovascular disease in 7 Latin American cities, as reported elsewhere \[[@B14]\]. With cardiovascular risk and clinical interventions in mind, the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria \[[@B2]\] were used to assess metabolic syndrome prevalence in CARMELA cities. The association of metabolic syndrome with mean common carotid artery intima-media thickness (CCAIMT), as a marker of carotid atherosclerosis, was also investigated.

Methods
=======

Study Design
------------

CARMELA was a multistage, cross-sectional epidemiologic study conducted between September 2003 and August 2005, in Barquisimeto, Venezuela; Bogota, Colombia; Buenos Aires, Argentina; Lima, Peru; Mexico City, Mexico; Quito, Ecuador; and Santiago, Chile. The study was conducted according to the Declaration of Helsinki and the Guides for Good Clinical Practice. Approximately 1,600 participants per city between the ages of 25 and 64 years were included, stratified by sex and age (10-year groups). The study was approved by an institutional review committee in all participating cities, and all subjects gave informed consent. Study methods are described in detail elsewhere \[[@B14]\].

Anthropometry
-------------

Waist circumference was measured at the midpoint between the last rib and the iliac crest with participants standing and wearing only undergarments.

Blood Glucose and Lipids
------------------------

Participants were asked to refrain from using laxatives containing glycerin for 48 hours and from consuming glycerin-containing products and other sweets for 24 hours prior to blood sampling. Blood was drawn in the fasting state; only water, black coffee, or unsweetened tea and medications other than antidiabetic medications were permitted during the 12 hours prior to sampling. Following the sampling, participants were allowed to resume their usual antidiabetic medication. Plasma glucose was assayed within 6 hours. Serum was assayed for high density lipoprotein cholesterol and triglycerides.

Blood Pressure
--------------

Blood pressure (at rest) was measured with the participant seated. Two readings were taken 5 minutes apart; if different by \>5 mm Hg, measurements were repeated until 2 concordant readings were obtained.

Measurement of CCAIMT
---------------------

Far wall CCAIMT was evaluated according to the Mannheim intima-media thickness consensus \[[@B15]\]. Both common carotid arteries were examined by B-mode ultrasonography with participants in the supine position, using phased array 7.5 MHz transducers and ultrasound apparatus no older than 7 years. M\'AthStd^®^software (Intelligence in Medical Technologies, Paris, France) automatically measured the CCAIMT; measurements were taken over a 10 mm length and averaged, and quality of acquisition was evaluated. Data were analyzed at a central laboratory at Intelligence in Medical Technologies, Paris, France.

Definitions
-----------

Diabetes was defined as a fasting plasma glucose level ≥ 7.0 mmol/l (126 mg/dL) \[[@B16]\] or self-reported diabetes. Metabolic syndrome was defined by NCEP ATP III criteria as the presence of 3 or more of the following: waist \>102 cm in men, \>88 cm in women; triglycerides ≥ 1.70 mmol/l (150 mg/dL); high density lipoprotein cholesterol (HDL-C) \<1.03 mmol/l (40 mg/dL) in men, \<1.29 mmol/l (50 mg/dL) in women; blood pressure ≥ 130/85 mm Hg; and fasting plasma glucose ≥ 6.11 mmol/l (110 mg/dL) or self-reported diabetes \[[@B2]\].

Statistical Analysis
--------------------

Statistical processing addressed the nonequal probability character of the sample and the structure of the design to generate data adjusted for the age and sex distribution of the population of each city. Means and prevalence along with their 95% confidence intervals were estimated by survey analysis procedures (SAS Software, Release 9.1, Cary, North Carolina, USA), taking into account the multistage stratified sampling design via CLUSTER and STRATA statements.

Results
=======

A total of 11,550 participants between the ages of 25 and 64 years were enrolled in CARMELA between September 2003 and August 2005. Data for 11,502 participants were evaluable for metabolic syndrome: Barquisimeto, n = 1,836; Bogotá, n = 1,550; Buenos Aires, n = 1,476; Lima, n = 1,645; Mexico City, n = 1,720; Quito, n = 1,627; and Santiago, n = 1,648. Per the study design, age and sex distribution was relatively even for each city.

Prevalence of the Metabolic Syndrome in the Overall CARMELA Population
----------------------------------------------------------------------

Metabolic syndrome was most prevalent in Mexico City (27%) and Barquisimeto (26%), followed by Santiago (21%) and Bogota (20%); lower prevalence was found in Lima (18%), Buenos Aires (17%), and Quito (14%). Overall, metabolic syndrome was more prevalent in women than men (22% vs 20%, respectively), with the exception of Buenos Aires and Barquisimeto where more men than women had metabolic syndrome. As expected, the prevalence of metabolic syndrome increased with age. In all cities, women showed markedly greater increase in metabolic syndrome with increasing age than men; in the oldest age group, female prevalence (range 25% to 49%) was greater than male prevalence (range 13% to 38%) in all cities except Buenos Aires (See Table [1](#T1){ref-type="table"} and Figure S1 in additional file [1](#S1){ref-type="supplementary-material"}). Of components of metabolic syndrome, the abdominal obesity was notably more prevalent in women than men, and the difference was accentuated in successively older age groups.

###### 

Prevalence (%) (95% confidence interval) in the nondiabetic population\* of the Metabolic Syndrome, according to NCEP ATP III.

                 **Age group**                                                               
  -------------- ------------------ ------------------ ------------------ ------------------ ------------------
  Barquisimeto                                                                               
   Men           19.7 (13.1-26.2)   27.2 (20.7-33.7)   32.4 (25.5-39.4)   38.1 (30.7-45.5)   23.0 (19.1-27.0)
   Women         11.6 (7.2-16.0)    23.9 (19.2-28.6)   37.7 (32.3-43.1)   47.8 (41.8-53.8)   22.7 (20.0-25.3)
  Bogota                                                                                     
   Men           10.7 (6.2-15.1)    18.5 (13.1-23.8)   25.9 (20.4-31.4)   30.1 (22.9-37.3)   14.7 (11.8-17.5)
   Women         8.3 (4.6-11.9)     16.8 (10.8-22.7)   36.2 (30.2-42.3)   48.6 (41.8-55.5)   18.2 (15.5-20.9)
  Buenos Aires                                                                               
   Men           11.8 (7.2-16.4)    21.8 (15.7-27.9)   26.6 (20.3-32.9)   33.0 (26.0-40.0)   17.3 (14.8-19.8)
   Women         3.3 (0.8-5.9)      7.5 (3.6-11.4)     16.9 (10.4-23.5)   24.6 (17.8-31.4)   9.7 (7.1-12.3)
  Lima                                                                                       
   Men           10.0 (5.9-14.2)    15.8 (9.0-22.5)    19.8 (14.1-25.4)   25.1 (18.2-32.1)   13.2 (10.6-15.8)
   Women         6.4 (3.2- 9.7)     18.7 (12.9-24.4)   34.8 (28.8-40.7)   36.8 (29.5-44.0)   17.6 (15.0-20.1)
  Mexico City                                                                                
   Men           22.2 (15.6-28.8)   22.6 (17.7-27.6)   33.5 (28.0-39.0)   37.2 (30.6-43.7)   22.4 (18.9-25.8)
   Women         16.5 (11.9-21.1)   27.4 (20.3-34.5)   35.5 (30.0-40.9)   49.3 (42.4-56.1)   22.2 (19.1-25.4)
  Quito                                                                                      
   Men           3.6 (0.7- 6.5)     6.3 (3.5- 9.1)     12.9 (8.2-17.6)    13.4 (8.6-18.2)    5.5 (3.9-7.1)
   Women         7.8 (3.6-12.1)     18.0 (11.8-24.2)   35.5 (29.3-41.6)   37.4 (31.1-43.7)   16.4 (13.5-19.3)
  Santiago                                                                                   
   Men           9.9 (5.8-14.0)     17.5 (12.0-23.0)   27.0 (20.8-33.1)   31.5 (25.5-37.4)   15.3 (12.8-17.9)
   Women         11.6 (7.3-15.9)    22.3 (16.0-28.6)   26.1 (20.4-31.7)   42.4 (36.4-48.5)   19.0 (16.0-22.0)

\*CARMELA participants excluding participants with fasting plasma glucose ≥ 7.0 mmol/l (126 mg/dL) and/or self-reported diabetes.

Prevalence of Specific Components of the Metabolic Syndrome
-----------------------------------------------------------

Table [2](#T2){ref-type="table"} reports the prevalence of each component of the metabolic syndrome within the population of all participants with metabolic syndrome (with or without a history of diabetes mellitus). Overall, 86% had high triglycerides, 86% had low HDL-C, and 60% were hypertensive. Across cities, abdominal obesity was present in 81% to 93% of women, and in 46% to 73% of men with metabolic syndrome.

###### 

Prevalence\* and 95% confidence interval of specific components of the metabolic syndrome in population with metabolic syndrome

                 **Abdominal obesity \>102 cm in men or \>88 cm in women**   **Triglycerides ≥ 1.70 mmol/l (150 mg/dL)**   **HDL-C \<1.03 mmol/l (40 mg/dL) in men or \<1.29 mmol/l (50 mg/dL) in women**   **Blood pressure ≥ 130/85 mm Hg or treatment**   **Glucose abnormalities^†^**
  -------------- ----------------------------------------------------------- --------------------------------------------- -------------------------------------------------------------------------------- ------------------------------------------------ ------------------------------
  Overall        76.3 (74.0-78.6)                                            85.9 (84.3-87.6)                              85.6 (83.8-87.4)                                                                 60.1 (57.7-62.5)                                 31.2 (28.9-33.2)
   Men           61.3 (57.2-65.5)                                            90.2 (88.2-92.1)                              82.7 (80.2-85.2)                                                                 68.0 (64.7-71.3)                                 32.6 (29.5-35.7)
   Women         88.1 (86.2-90.0)                                            82.6 (80.2-85.0)                              87.9 (85.9-90.0)                                                                 53.8 (50.8-56.9)                                 30.1 (27.1-33.0)
  Barquisimeto                                                                                                                                                                                                                                               
   Men           56.6 (49.1-64.1)                                            90.3 (85.9-94.8)                              92.9 (89.6-96.2)                                                                 82.2 (76.7-87.8)                                 23.1 (17.4-28.8)
   Women         84.0 (79.6-88.3)                                            78.7 (73.9-83.5)                              96.4 (94.8-98.0)                                                                 63.6 (57.3-69.9)                                 19.4 (15.5-23.3)
  Bogota                                                                                                                                                                                                                                                     
   Men           45.8 (35.6-56.1)                                            92.1 (87.5-96.8)                              92.9 (89.1-96.8)                                                                 57.6 (48.8-66.3)                                 40.6 (32.1-49.2)
   Women         86.0 (81.5-90.5)                                            83.3 (78.3-88.2)                              93.7 (90.2-97.2)                                                                 49.8 (42.2-57.4)                                 28.6 (22.2-34.9)
  Buenos Aires                                                                                                                                                                                                                                               
   Men           73.1 (65.6-80.5)                                            77.5 (71.1-84.0)                              67.7 (60.2-75.2)                                                                 93.2 (89.5-96.8)                                 31.8 (24.0-39.7)
   Women         88.9 (82.9-94.9)                                            65.4 (56.7-74.0)                              79.9 (72.4-87.3)                                                                 77.3 (68.3-86.4)                                 31.1 (21.3-40.9)
  Lima                                                                                                                                                                                                                                                       
   Men           55.3 (46.5-64.2)                                            87.3 (81.8-92.7)                              93.4 (89.0-97.7)                                                                 70.5 (62.9-78.0)                                 30.7 (22.0-39.5)
   Women         80.8 (75.2-86.3)                                            82.6 (76.9-88.4)                              97.9 (95.8-100.0)                                                                51.7 (44.3-59.1)                                 24.0 (18.6-29.3)
  Mexico City                                                                                                                                                                                                                                                
   Men           72.7 (65.9-79.5)                                            93.0 (89.7-96.3)                              78.0 (73.7-83.9)                                                                 58.3 (52.8-63.7)                                 30.4 (24.5-36.2)
   Women         93.1 (90.6-95.5)                                            85.7 (80.0-91.3)                              77.7 (73.2-82.1)                                                                 52.8 (47.3-58.2)                                 35.2 (27.9-42.6)
  Quito                                                                                                                                                                                                                                                      
   Men           48.8 (36.3-61.4)                                            97.9 (94.8-101.0)                             83.9 (75.8-92.1)                                                                 62.3 (48.1-76.5)                                 33.4 (22.5-44.3)
   Women         90.1 (85.5-94.7)                                            83.3 (79.0-87.7)                              92.0 (88.9-95.1)                                                                 37.0 (28.7-45.2)                                 32.6 (26.1-39.1)
  Santiago                                                                                                                                                                                                                                                   
   Men           60.7 (51.9-69.5)                                            93.0 (89.6-96.3)                              73.5 (66.4-80.7)                                                                 76.6 (69.1-84.0)                                 31.4 (24.9-37.9)
   Women         90.6 (86.7-94.4)                                            82.9 (77.6-88.2)                              86.6 (81.9-91.2)                                                                 57.1 (50.6-63.6)                                 31.1 (24.1-38.1)

\*Prevalence among participants with metabolic syndrome, with or without previously diagnosed diabetes mellitus.

^†^Participants with fasting plasma glucose \>6.11 mmol/l (110 mg/dL) or previous diagnosis of diabetes mellitus.

Prevalence of the Metabolic Syndrome in Participants With Specific Components
-----------------------------------------------------------------------------

Prevalence of the metabolic syndrome in subsets of the overall population with specific components of the syndrome is reported in Table [3](#T3){ref-type="table"}. Overall, approximately two-thirds of men with abdominal obesity or glucose abnormalities, and approximately 60% to 70% of women with high triglycerides, hypertension, or glucose abnormalities had the full metabolic syndrome. In all cities except Mexico City, the prevalence of metabolic syndrome among participants with low HDL-C was fairly low. Prevalence of the syndrome among women with high triglycerides was notably higher than among men in all cities except Barquisimeto and Buenos Aires.

###### 

Prevalence (%)(95% confidence interval) of the metabolic syndrome among subsets of participants\* with each of the 5 NCEP ATP III risk factor components of the syndrome

                 **Abdominal obesity \>102 cm in men or \>88 cm in women**   **Triglycerides ≥ 1.70 mmol/l (150 mg/dL)**   **HDL-C \<1.03 mmol/l (40 mg/dL) in men or \<1.29 mmol/l (50 mg/dL) in women**   **Blood pressure ≥ 130/85 mm Hg or treatment**   **Glucose abnormalities**^†^
  -------------- ----------------------------------------------------------- --------------------------------------------- -------------------------------------------------------------------------------- ------------------------------------------------ ------------------------------
  Overall        53.3 (51.0-55.5)                                            45.7 (43.9-47.5)                              34.6 (33.0-36.2)                                                                 52.5 (50.3-54.7)                                 71.6 (68.3-74.8)
   Men           64.0 (60.3-67.7)                                            36.2 (34.0-38.4)                              35.5 (33.0-38.0)                                                                 47.5 (44.7-50.2)                                 70.5 (66.4-74.7)
   Women         48.7 (45.9-51.6)                                            59.0 (56.2-61.9)                              34.0 (32.0-36.0)                                                                 58.7 (55.6-61.8)                                 72.5 (67.7-77.2)
  Barquisimeto                                                                                                                                                                                                                                               
   Men           75.7 (66.9-84.5)                                            50.3 (44.5-56.1)                              34.5 (29.1-39.9)                                                                 60.2 (53.7-66.7)                                 82.1 (72.9-91.2)
   Women         61.1 (55.9-66.3)                                            66.9 (62.6-71.2)                              32.4 (28.5-36.3)                                                                 59.8 (54.1-65.5)                                 70.3 (59.4-81.2)
  Bogota                                                                                                                                                                                                                                                     
   Men           77.1 (68.5-85.7)                                            32.1 (27.7-36.5)                              29.4 (25.2-33.7)                                                                 53.1 (45.9-60.2)                                 71.1 (60.3-81.9)
   Women         55.0 (49.0-60.9)                                            55.0 (48.4-61.6)                              28.5 (25.2-31.9)                                                                 64.8 (56.2-73.4)                                 61.6 (50.1-73.1)
  Buenos Aires                                                                                                                                                                                                                                               
   Men           56.6 (50.3-62.8)                                            57.2 (49.9-64.5)                              50.1 (43.3-57.0)                                                                 38.4 (34.2-42.5)                                 70.8 (60.1-81.6)
   Women         36.0 (29.7-42.2)                                            62.3 (53.1-71.4)                              31.7 (25.1-38.3)                                                                 31.7 (25.1-38.4)                                 68.6 (55.3-81.9)
  Lima                                                                                                                                                                                                                                                       
   Men           73.7 (65.0-82.4)                                            35.1 (29.4-40.7)                              22.9 (18.9-26.8)                                                                 46.4 (39.1-53.6)                                 74.5 (63.2-85.8)
   Women         50.9 (44.3-57.5)                                            61.5 (55.2-67.8)                              24.3 (21.1-27.5)                                                                 64.1 (56.7-71.5)                                 76.6 (65.7-87.4)
  Mexico City                                                                                                                                                                                                                                                
   Men           59.6 (52.4-66.8)                                            38.3 (33.6-43.0)                              58.8 (51.7-65.9)                                                                 61.8 (55.2-68.5)                                 71.1 (64.7-77.4)
   Women         46.7 (40.2-53.2)                                            59.3 (53.5-65.1)                              53.0 (47.1-58.9)                                                                 67.7 (60.3-75.1)                                 79.5 (71.6-87.5)
  Quito                                                                                                                                                                                                                                                      
   Men           66.2 (52.3-80.1)                                            14.5 (11.1-17.9)                              22.6 (16.9-28.2)                                                                 34.1 (25.7-42.5)                                 44.5 (31.8-57.2)
   Women         46.2 (40.9-51.5)                                            51.3 (42.9-59.7)                              38.6 (32.8-44.4)                                                                 62.2 (53.7-70.7)                                 71.9 (62.1-81.7)
  Santiago                                                                                                                                                                                                                                                   
   Men           61.1 (52.6-69.7)                                            36.4 (31.5-41.3)                              44.8 (38.4-51.1)                                                                 39.5 (34.1-44.8)                                 68.1 (58.8-77.3)
   Women         47.8 (42.6-52.9)                                            61.9 (56.1-67.8)                              43.3 (37.8-48.9)                                                                 57.6 (51.7-63.5)                                 74.9 (65.4-84.5)

\*All participants, with or without diabetes mellitus, were grouped by presence of specific components, and prevalence of metabolic syndrome within each group is reported here.

^†^All participants with fasting plasma glucose \>6.11 mmol/l (110 mg/dL) or previous diagnosis of diabetes mellitus.

Prevalence of Metabolic Syndrome Among Participants Without Diabetes
--------------------------------------------------------------------

Table [4](#T4){ref-type="table"} reports the prevalence of the number of components of the metabolic syndrome among CARMELA participants without a history of diabetes mellitus. In all cities, \>60% of the participants had at least 1 component of the metabolic syndrome. As in the overall CARMELA population, the prevalence of metabolic syndrome in the nondiabetic population was higher in women than men, except in Barquisimeto and Buenos Aires.

###### 

Prevalence (%) (95% confidence interval) in the nondiabetic population\* of 1 to 5 of the NCEP ATP III risk factor components of the metabolic syndrome and diagnosis of metabolic syndrome

                 **Number of Components**                                                                            
  -------------- -------------------------- ------------------ ------------------ ------------------ --------------- ---------------
  Overall        23.4 (22.3-24.5)           32.8 (31.7-34.0)   26.5 (25.4-27.6)   13.0 (12.2-13.8)   4.0 (3.6-4.4)   0.3 (0.2-0.4)
   Men           24.6 (23.1-26.2)           30.8 (29.1-32.4)   28.5 (26.9-30.0)   12.2 (11.1-13.4)   3.6 (3.0-4.1)   0.3 (0.1-0.5)
   Women         22.3 (20.8-23.8)           34.7 (33.0-36.3)   24.8 (23.3-26.2)   13.7 (12.5-14.8)   4.3 (3.8-4.9)   0.3 (0.1-0.4)
  Barquisimeto                                                                                                       
   Men           14.1 (11.2-16.7)           32.6 (28.3-37.0)   30.3 (26.5-34.1)   15.8 (12.8-18.8)   6.7 (4.7-8.8)   0.5 (0.0-1.0)
   Women         13.4 (10.9-16.0)           37.5 (33.8-41.2)   26.4 (23.4-29.5)   16.3 (14.0-18.5)   6.2 (4.7-7.8)   0.2 (0.0-0.3)
  Bogota                                                                                                             
   Men           21.6 (18.1-25.0)           30.7 (26.6-34.9)   33.0 (29.4-36.6)   11.4 (8.6-14.2)    3.0 (1.8-4.1)   0.3 (0.0-0.7)
   Women         17.6 (14.3-20.9)           35.4 (31.9-38.9)   28.8 (25.5-32.1)   14.0 (11.2-16.8)   4.0 (2.9-5.2)   0.2 (0.0-0.4)
  Buenos Aires                                                                                                       
   Men           28.5 (25.1-31.9)           30.2 (27.3-33.1)   24.0 (20.4-27.5)   12.7 (10.5-15.0)   4.4 (2.9-5.9)   0.2 (0.0-0.5)
   Women         37.7 (33.8-41.5)           36.7 (32.8-40.6)   15.9 (13.0-18.8)   7.5 (5.4-9.6)      2.1 (0.8-3.3)   0.1 (0.0-0.4)
  Lima                                                                                                               
   Men           21.5 (18.0-25.0)           35.8 (32.0-39.7)   29.5 (26.0-33.0)   9.7 (7.5-11.8)     3.2 (1.9-4.5)   0.3 (0.0-0.6)
   Women         12.1 (9.5-14.7)            44.2 (40.4-48.1)   26.1 (22.7-29.5)   13.2 (10.9-15.3)   4.2 (3.0-5.5)   0.2 (0.0-0.5)
  Mexico City                                                                                                        
   Men           23.7 (20.5-27.0)           26.0 (23.4-28.5)   27.9 (24.7-31.1)   17.3 (14.1-20.5)   4.6 (3.2-6.0)   0.5 (0.0-1.0)
   Women         24.3 (20.7-27.8)           27.5 (24.1-31.0)   26.0 (22.9-29.0)   16.7 (14.0-19.4)   5.0 (3.7-6.3)   0.5 (0.0-1.0)
  Quito                                                                                                              
   Men           39.2 (34.8-43.5)           32.5 (28.9-36.0)   22.8 (19.8-25.9)   4.3 (2.9-5.8)      1.1 (0.4-1.8)   0.1 (0.0-0.2)
   Women         30.5 (26.9-34.1)           30.9 (27.2-34.5)   22.2 (18.8-25.7)   13.4 (10.8-16.1)   2.7 (1.7-3.6)   0.3 (0.0-0.6)
  Santiago                                                                                                           
   Men           28.6 (24.5-32.6)           29.8 (25.6-33.9)   26.3 (22.7-29.9)   11.7 (9.5-14.1)    3.3 (2.0-4.5)   0.3 (0.0-0.7)
   Women         28.6 (24.8-32.3)           30.5 (26.9-34.2)   21.9 (19.1-24.8)   13.3 (10.8-15.8)   5.5 (3.8-7.1)   0.2 (0.0-0.5)

\*CARMELA participants excluding participants with fasting plasma glucose ≥ 7.0 mmol/l (126 mg/dL) and/or self-reported diabetes.

Metabolic Syndrome and Carotid Atherosclerosis
----------------------------------------------

In both men and women overall, mean CCAIMT increased steeply with increasing numbers of metabolic syndrome components (Table [5](#T5){ref-type="table"} and Figure S2 in additional file [1](#S1){ref-type="supplementary-material"}). Similarly, the prevalence of carotid plaque also increased with increasing numbers of components and overall, was approximately 50% more prevalent in both men and women with metabolic syndrome than those without. In all cities, mean CCAIMT and prevalence of plaque were higher in participants with metabolic syndrome than those without.

###### 

Mean CCAIMT (mm), prevalence (%) and 95% confidence intervals, of carotid plaque according to the number of components of the metabolic syndrome by NCEP ATP III criteria in the CARMELA participants\*

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Number of components**       **0**           **1**           **2**           **3**             **4**             **5**             **No metabolic syndrome**   **Metabolic syndrome**
  ------------------------------ --------------- --------------- --------------- ----------------- ----------------- ----------------- --------------------------- ------------------------
  Mean CCAIMT                                                                                                                                                      

  Men                            0.623\          0.644\          0.665\          0.688\            0.707\            0.731\            0.645\                      0.695\
                                 (0.616-0.629)   (0.637-0.650)   (0.658-0.672)   (0.679-0.697)     (0.694-0.720)     (0.701-0.761)     (0.640-0.650)               (0.687-0.702)

  Women                          0.624\          0.624\          0.645\          0.668\            0.709\            0.704\            0.631\                      0.682\
                                 (0.617-0.632)   (0.618-0.631)   (0.639-0.652)   (0.662-0.675)     (0.696-0.721)     (0.685-0.723)     (0.626-0.636)               (0.676-0.688)

  Prevalence of carotid plaque                                                                                                                                     

  Men                            4.0 (2.7-5.2)   7.2 (5.7-8.6)   7.8 (6.2-9.4)   9.3 (6.9-11.7)    9.7 (5.9-13.4)    11.4 (3.4-19.4)   6.4 (5.5-7.4)               9.5 (7.4-11.6)

  Women                          4.9 (3.5-6.2)   7.4 (5.9-8.8)   7.8 (6.3-9.4)   10.9 (8.5-13.3)   11.7 (8.1-15.4)   12.5 (6.2-18.8)   6.8 (5.9-7.7)               11.2 (9.3-13.2)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*CARMELA survey participants, including those with previous history of diabetes mellitus.

CCAIMT = carotid artery intima-media thickness

Discussion
==========

The CARMELA study reports overall prevalence of 21% of metabolic syndrome by NCEP ATP III criteria in the 7 Latin American cities studied. Profiles of the metabolic syndrome according to sex varied among cities. Among the overall population and the nondiabetic population, the highest prevalence of metabolic syndrome was found in Barquisimeto and Mexico City. Women of Bogota, Lima, Quito, and Santiago had greater prevalence of metabolic syndrome than their male counterparts, while the opposite was true in Buenos Aires. Not surprisingly, prevalence of metabolic syndrome increased with age, strikingly so in women. Participants with metabolic syndrome had higher mean CCAIMT and prevalence of carotid plaque than those without the syndrome.

The prevalence of metabolic syndrome found in CARMELA approximates prevalence estimates (23% to 27%) in the United States \[[@B6],[@B13]\]. Direct comparison with other Latin America studies using NCEP ATP III criteria show CARMELA prevalence to be consistent with prevalence in Mexico \[[@B17],[@B18]\]. Also by NCEP ATP III criteria, 31% of a population of Zulia State, Venezuela \[[@B19]\], and 12% and 26% of men and women of Lima \[[@B18]\], respectively, were found to have metabolic syndrome. CARMELA reports lower prevalence in Barquisimeto than elsewhere in Venezuela, and prevalence that is less disparate between the sexes of Lima; however, CARMELA targeted a much broader population base than in the aforementioned study in Lima. In the Estudio Peruano de Prevalencia de Enfermedades Cardiovasculares, or Peruvian Study of the Prevalence of Cardiovascular Risk Factors (PREVENCION) study in another urban region of Peru, 14% and 23% of men and women, respectively, were found to have the syndrome \[[@B20]\].

Whereas it has been suggested that the burden of metabolic syndrome is growing in younger populations, especially in developing regions \[[@B21]\], metabolic syndrome increases with age as CARMELA results confirm. Elevated body weight, waist circumference, and low HDL-C levels have been found to be more common contributors to metabolic syndrome in women, while blood pressure and apolipoprotein B have been found to be more common contributors in men \[[@B22]\]. Obesity in women is increasing faster than in men \[[@B23]\] and the metabolic syndrome increases in a parallel manner. In many women, menopause is accompanied by the emergence of features of the metabolic syndrome and increased cardiovascular risk, whether as a direct result of ovarian failure or indirectly related to central adipose redistribution \[[@B23],[@B24]\]. With this constellation of factors, it has even been suggested that the metabolic syndrome should be defined by different criteria in men and women \[[@B22]\]. CARMELA results illustrate the amplified increase in metabolic syndrome in women as opposed to men as women reach menopausal age. A study of post-menopausal Ecuadorian women \[[@B25]\] revealed an overall prevalence of metabolic syndrome of 42%, similar to that found in CARMELA, with prevalence of hypertension, abdominal obesity, and low HDL-C similar to that in women in the older 2 CARMELA age groups. In a broader study of postmenopausal Latin American women, rates of metabolic syndrome in women of Buenos Aires were higher and those of Bogota, Lima, and Santiago, similar to those of women in the oldest 2 CARMELA age groups \[[@B26]\]. Although in all CARMELA cities, older women showed strikingly higher abdominal obesity rates than men, high rates of abdominal obesity were found in women of all age groups.

In designing targeted programs for detection and treatment of metabolic syndrome, CARMELA provides crucial data on the sensitivity and predictive value of each component. On the one hand, of the general population of men in CARMELA cities (except for Quito where lower prevalence of metabolic syndrome in men is noted), approximately 70% of those with glucose abnormalities, approximately two-thirds of those with abdominal obesity, and half with hypertension, will have the full syndrome. Of the general population of women in CARMELA cities, nearly three-quarters of those with glucose abnormalities, and approximately 50% to 60% with abdominal obesity, high triglycerides, or hypertension, will have the full metabolic syndrome (Table [2](#T2){ref-type="table"}). On the other hand, once metabolic syndrome is diagnosed, the shape of the syndrome is characterized by predominance of hypertension, low HDL-C and high triglycerides in men, and predominance of abdominal obesity, high triglycerides, and a remarkable predominance of low HDL-C in women (Table [3](#T3){ref-type="table"}). Thus, hypertension, low HDL-C, and high triglycerides in men and low HDL-C in particular, along with high triglycerides and abdominal obesity in women, are highly specific indicators of the syndrome. CARMELA provides data which confirms the likelihood of finding other specific components, once metabolic syndrome is diagnosed. Although the metabolic syndrome predicts diabetes along with cardiovascular risk, glucose abnormalities in and of themselves are not particularly specific to the full syndrome. This notion is confirmed by the similar prevalence of metabolic syndrome in CARMELA populations that both include and exclude diabetes. Since the metabolic syndrome is epitomized by the development of diabetes, its presence in the nondiabetic population is of particular importance.

To our knowledge, this is the first study that provides evidence of a relationship between the occurrence of the metabolic syndrome and the presence of carotid atherosclerosis in the Latin American population. A large study in Italy reported increased incidence of carotid plaques and stenosis over 5 years of follow-up in participants with metabolic syndrome \[[@B9]\]. Metabolic syndrome has also been associated with incident stroke in both black and white populations in the United States \[[@B6]\] and with higher carotid intima-media thickness and prevalence of plaques in elderly French individuals \[[@B27]\]. Metabolic syndrome has also been associated with tissue characteristics of the intima-media complex in the carotid artery \[[@B28]\], and the increasing number of components of the metabolic syndrome have also been related to higher carotid artery stiffness \[[@B29]\]. In other studies, the association between metabolic syndrome and carotid atherosclerosis has been reported to be stronger in women than men \[[@B30]\], however, in the CARMELA study it seems to be quite similar for men and women. Carotid intima-media thickening as an indicator of atherosclerosis in other vascular beds \[[@B31]\] is a strong predictor of future cardiovascular events \[[@B32]\]. The relationship between metabolic syndrome and carotid atherosclerosis noted in CARMELA enhances previous findings of metabolic syndrome as a cardiovascular disease predictor \[[@B3],[@B7],[@B9]\].

The value of CARMELA lies in its carefully constructed sampling of populations by age and sex to elucidate prevalence of metabolic syndrome components. Urban vs rural and ethnic differences in prevalence of metabolic syndrome have been reported in a variety of Latin American settings \[[@B33]\] and should be investigated further. Genetic predispositions to the metabolic syndrome \[[@B34]\], along with cultural and nutritional variations, also need investigation given Latin America\'s unique conglomeration of indigenous and immigrant populations. The obesity epidemic clearly affects the prevalence of metabolic syndrome among women but also extends to the young; CARMELA\'s lowest age range (25 to 34 years) may not have fully encompassed populations at risk, nor did CARMELA include increasingly older populations, which until now have borne the brunt of chronic disease. Rigorous studies like CARMELA should aid in designing targeted solutions to increasing rates of metabolic syndrome and its consequences.

In the Shape of the Nations Survey, 39% of participants worldwide who visited primary care physicians were overweight or obese, but only 58% of primary care physicians recognized that abdominal obesity was a significant risk factor for cardiovascular disease, and 45% reported that they never measured waist circumference \[[@B35]\]. As alarming as these statistics are, CARMELA findings reinforce the notion that metabolic syndrome is prevalent in urban Latin America and should be sought in the presence of even 1 component of the syndrome. Likewise, carotid atherosclerosis in Latin American individuals should spur healthcare providers to seek evidence of metabolic syndrome components and effect appropriate interventions. Guidelines for treatment of specific components in the context of the full metabolic syndrome are being developed \[[@B2]\] and should be promoted by healthcare educators and providers. The chronic disease burden consequent to metabolic syndrome will be extensive and expensive in Latin America if studies like CARMELA are ignored.

Conclusion
==========

CARMELA reports high prevalence of metabolic syndrome in 7 Latin American cities. Although rates varied between cities, there was a striking increase in the prevalence of metabolic syndrome with age, especially in women. CARMELA provides evidence for the association of metabolic syndrome with evidence of carotid atherosclerosis\--namely increasing mean CCAIMT and plaque with increasing numbers of components of the syndrome, and overall higher mean CCAIMT and plaque in participants with the syndrome compared with those without. It is incumbent on government agencies and the medical community to address current prevalence of metabolic syndrome in order to prevent the dire consequences of increased burden of disease.
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